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Abstract
Background: Cancer is among the leading contributors to morbidity and mortality in the Pacific, but the magnitude of
the problem and the potential for prevention have not been comprehensively studied. Over the past decade, cervical
cancer has been the most common cancer among women in Fiji with an age standardised cervical cancer incidence
rate of 51 per 100,000. This rate is among the highest in the South Pacific region and in the world. This high cervical
cancer incidence rate is likely linked to the low cervical screening rate, but it points also to the possibility of a high
burden of human papillomavirus (HPV) infection.
Methods: We conducted a population-based survey in Fiji to provide information on human papillomavirus (HPV)
prevalence, and the distribution of individual HPV types in a Fijian health-sub-district. We included 1,261 women aged
between 16 and 64 years. A general primer GP5+/6+mediatedpolymerase chain reaction (PCR) assay was used for HPV
testing of 44 HPV types.
Results: The crude HPV prevalence in 1,244 women with an adequate HPV sample was 24.0% (95% confidence interval
(CI), 21.7-26.4%) and the corresponding age standardised prevalence was 25.5% (95% CI, 23.1-28.1%). The prevalence of
high-risk HPV types was 13.6% (95% CI, 11.8-15.6%). Among 1,192 women with adequate cytological results, 13 (1.1%)
showed cervical abnormalities, the majority of which were high-grade intraepithelial lesions or worse. HPV prevalence
declined from 35.8% in women aged <25 years to 18.6% in those aged 55–64 years of age. After adjustment, the only
variables significantly associated with HPV-positivity were age (ranging from odds ratio (OR) 0.57 (95% CI, 0.36-0.89) for
25–34 year-old-women to OR 0.43 (95% CI, 0.20-0.89) for 55–64 year-old-women) and ‘husband’s extramarital sexual
relationships’ (OR 1.69; 95% CI, 1.17-2.34).
Conclusion: These findings on HPV provide key information for future policy decisions on the most appropriate
methods of cervical cancer prevention in Fiji and in the Pacific region.
Keywords: Human papillomavirus (HPV), HPV genotypes, Cervical neoplasia, Cervical screening, Fiji
Background
There has been considerable interest and research on
non-communicable diseases throughout the South Pacific
over the last 40 years [1]. This has not been the case with
cancer research however, and there have been relatively
few publications [2]. Cancer is among the leading contrib-
utors to morbidity and mortality in the Pacific [3], but the
magnitude of the problem, the key risk factors, and the
potential for prevention have not been comprehensively
studied [4]. The patterns of cancer vary widely with some
Pacific islands having high incidence rates for infection-
related cancers, such as cervical and liver cancers, while
others demonstrate a more westernised pattern of cancer
prevalence, predominantly colon and breast cancers [4].
The Fiji Islands consist of 322 islands and 840,201 in-
habitants [5]. The British colonised Fiji in 1874 and the
Indian labourers brought for the sugar cane plantations
now account for 43% of the population, with indigenous
Fijians (partly Tongan and Melanesian ancestry) account-
ing for just over 50% [5]. Life expectancy is similar for
both Indian and indigenous Fijians (64 years in males;
68 years in females) [5].* Correspondence: s.foliaki@massey.ac.nz1Centre for Public Health Research, Massey University, PO Box 756,
Wellington 6140, New Zealand
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Over the past decade, cervical cancer has been the
most common cancer among women in Fiji with an age
standardised cervical cancer incidence rate of 51 per
100,000 [4]. This rate is among the highest in the South
Pacific region [6] and in the world [7]. This high cervical
cancer incidence rate is likely linked to the low cervical
screening rate, but it points also to the possibility of a
high burden of human papillomavirus (HPV) infection.
HPV genotyping of cervical cancer and cervical intrae-
pithelial neoplasia specimens taken in 2003 to 2007 from
296 women at Fiji’s Colonial War Memorial Hospital,
showed that HPV16 and 18 were the most common ge-
notypes (77%), followed by HPV 31 (9%) and HPV 52
(7%) [8]. However, there have been no studies of the
general population prevalence of HPV in Fiji, and only
one elsewhere in the Pacific – in Vanuatu in 2009-2010
[9].
We therefore conducted a study to determine the preva-
lence of HPV infection, cervical abnormalities, and other
cervical cancer risk factors among a sample of women in
the Valelevu health-sub-district of Suva, the Fijian capital.
The study was a collaboration between Massey University
and the International Agency for Research on Cancer
(IARC), in partnership with the Fiji Ministry of Health’s
Cervical Cancer Screening Programme.
Results
A total of 1,261 women aged 16–63 years (mean 36.9 years)
participated in the study, and 944 (75%) lived in the study
area. All 1,261 women provided a sample for HPV analysis,
17 were beta-globin negative, leaving 1,244 available for
HPV analysis. A total of 1,192 cervical samples were ad-
equate for, and assessed for, cytology.
Table 1 gives the findings for the prevalence of the
various HPV types in 1,244 women for whom a valid
HPV result was obtained. The overall crude prevalence
of HPV infection was 24.0% (21.7-26.4%) and the corre-
sponding age standardized prevalence was 25.5% (95%
CI, 23.1-28.1%). The corresponding estimate for HR
types was 13.6% (11.8-15.6%), and that for LR types was
14.9% (13.0-17.0%). HPV 16 was the most common type
(4.0%; Table 1). Among HR types, HPV 16, 52, 56 and
59 were each found in ≥1.5% of women overall. HPV 18
was found in 1.1% of women. Among LR types HPV 42
was the most common (3.0% overall), while 66, 70, 81
and Jc9710 were each found among ≥1.4% of women.
HPV 6 and 11 were detected in 0.5% and 0.2% of
women, respectively. Multiple HPV types accounted for
29.9% of HPV-positive women.
Figure 1 shows the age-specific prevalence of HPV in
1,244 women (i.e. all of the women for whom a valid HPV
result was obtained), 298 of whom were HPV-positive,
classified into: (i) HPV 16/18; (ii) any HR; (iii) any LR; and
(iv) any HPV genotype. Prevalence decreased from 35.8%
in women aged less than 25 years to 18.6% in women aged
55–64 years. Similar patterns were observed for each
group of HPV types. HPV16 and 18 accounted for 36.7%
of HR HPV-positivity in the general female population,
ranging from 33.3% among women aged 16-24 years to
50.0% among women aged 55–64 years.
Among the 1,244 women who had a valid HPV result,
39 (3%) had inadequate Pap smear results. Among women
with adequate cytological results, cervical abnormalities
were diagnosed in 13 women, of whom 84.6% were HPV-
positive. The proportion of cytological abnormalities var-
ied from 1.7% in women aged 25–34 years, down to 0.34%
in women aged 35–44 years.
Cytological abnormalities included four ASCUS (one
HPV-negative; 16 and 18; 81, Jc9710 and 52; 66), one low-
grade abnormality (HPV45), one atypical squamous cells -
cannot exclude high-grade squamous intraepithelial lesion
(ASC-H) (HPV 42), and six high-grade abnormalities, (one
HPV-negative; HPV 6 and 16; 6 and 52; 53 and 51; 66 and
58; 56), and one clinically detectable invasive cervical
cancer (HPV16). All of the women with cytological abnor-
malities were recalled for follow-up.
Table 2 shows the relationships between HPV positivity
and various potential risk factors. The only statistically sig-
nificant positive associations were for separated/divorced/
widowed versus currently married women (OR = 1.68;
1.04-2.73) and report of husband’s extramarital sexual re-
lationships (OR = 1.69; 1.20-2.38). A non-significant posi-
tive association was found between HPV positivity and
nulliparity (compared with one full-term pregnancy) but
no significant difference by number of full-term pregnan-
cies. The association with being separated/divorced/
widowed was mainly driven by findings in women aged 45
or older (Figure 2). It was greatly diminished by ad-
justment for husband’s extramarital sexual relationships
(Table 2).
Discussion
This is the first HPV prevalence survey to be conducted in
Fiji, a country with high cervical cancer rates. It revealed
an important prevalence of HPV (24.0%) in the general fe-
male population, similar to that found in the only other
HPV prevalence survey conducted (to date) in the Pacific,
in Vanuatu [9] (although surveys have also been con-
ducted in specific populations in some countries: Ha-
waiian women [10] and indigenous women in Australia
[11]). The survey in Vanuatu [9] found a similar age-
standardised prevalence of 25.0%. Findings in Fiji can
be validly compared to those in Vanuatu and in the
other ~25 IARC HPV surveys, for which only Guinea
(51.5%) [12] and Mongolia (35%) [13] showed higher
prevalence, since they are based on the same study design
and HPV testing methods.
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HR HPV prevalence across the IARC HPV prevalence
surveys has been shown to be strongly correlated with
cervical cancer incidence rates [14]. This correlation is
particularly strong for HR HPV prevalence among
women aged 55-64 [14], and a HR HPV prevalence of
10% in this age group in Fiji would be predictive of the
observation of a high cervical cancer risk (51 cases per
100,000 person years) [4].
HPV16 was the most frequently detected HPV type.
This is consistent with a meta-analysis showing that
HPV16 is the most common cervical infection world-
wide in all grades of cervical diagnoses [15]. The distri-
bution of the four most common cervical HR HPV
genotypes in our study was HPV16, 52, 56 and 59 identi-
cal to those reported in Vanuatu [9]. HPV18 was not
found as commonly in the current study as in other
studies in Asia or North America [15], a phenomena
that was also observed in Vanuatu [9].
The only risk factor found to be significantly positively
associated with cervical HPV infection in the multiple-
adjusted analysis was the husband’s extramarital sexual re-
lationships (OR = 1.66; 95% CI, 1.17-2.34). However, we
did not have detailed information on the women’s sexual
behaviour as it was considered inappropriate to ask ques-
tions about number of sexual partners to Fijian women in
the current study. A positive association with being sepa-
rated/divorced/widowed was present in the age-adjusted
analysis and it was consistent with findings in previous
IARC surveys [16]. Notably, significantly higher HPV
prevalence was found in single/separated/divorced women
aged 45 years or older than in their married counterparts.
This difference is likely due to relatively high-risk sexual
behaviour in this group of unmarried middle-aged women
or in their male sexual partners, i.e., a feature that may
vary according to the age assortativity of sexual partner-
ships in different populations [17].
The strengths of this study include the relatively large
number of women surveyed and the comparability of study
methods and our findings with those of other IARC sur-
veys [12,18-21]. The main limitation of the study was that
we were unable to obtain a genuinely random population
sample. This occurred because of the absence of a reliable
Table 1 Prevalence of human papillomavirus (HPV) types
among 1,244 women, Fiji 2010-2011
HPV type Total (n = 1,244)a
Single Multiple Total (%)
HPV- - - 946 76.0
HPV+ 209 89 298 24.0
High-risk HPV+ 141 28 169 13.6
Low-risk HPV+ 151 34 185 14.9
High-risk infections
16 43 7 50 4.0
18 9 5 14 1.1
31 9 6 15 1.2
33 1 4 5 0.4
34 0 0 0 0.0
35 10 3 13 1.0
39 4 2 6 0.5
45 9 8 17 1.4
51 7 3 10 0.8
52 15 4 19 1.5
56 17 10 27 2.2
58 6 0 6 0.5
59 10 12 22 1.8
68 1 2 3 0.2
Low-risk infections
6 4 2 6 0.5
11 1 2 3 0.2
26 0 1 1 0.1
30 2 3 5 0.4
32 1 2 3 0.2
40 2 4 6 0.5
42 28 9 37 3.0
43 6 7 13 1.0
44 1 0 1 0.1
53 5 4 9 0.7
54 2 2 4 0.3
55 1 1 2 0.2
61 1 0 1 0.1
64 0 0 0 0
66 15 3 18 1.4
67 10 2 12 1.0
69 1 0 1 0.1
70 16 4 20 1.6
72 3 0 3 0.2
73 0 1 1 0.1
81 9 8 17 1.4
82 6 3 9 0.7
83 5 1 6 0.5
Table 1 Prevalence of human papillomavirus (HPV) types
among 1,244 women, Fiji 2010-2011 (Continued)
84 3 1 4 0.3
85 3 1 4 0.3
86 3 1 4 0.3
97 0 0 0 0.0
Cp6108 5 1 6 0.5
Jc9710 14 12 26 2.1
Low-risk unspecified 4 0 4 0.3
a68 inadequate cytology are included in the total.
Foliaki et al. Infectious Agents and Cancer 2014, 9:14 Page 3 of 8
http://www.infectagentscancer.com/content/9/1/14
residential list, and a lack of specific postal addresses, as
well as the mobility of the population. This led to the in-
clusion of women who worked in the study area, but who
did not necessarily live there. However, it is unlikely that
the non-representativeness of the sample had a major im-
pact on the study findings since the HPV prevalence was
similar whether or not we included the women that lived
outside of the study area (data not shown). Although the
exact participation rate for the study is difficult to estimate,
the age distribution of the participating women was similar
to the age distribution of Fiji women in the latest census
(2007), except for an under-representation of women aged
16 to 24 years (12% in our study compared with 29%
among Fiji’s female population [5]). Another limitation was
that it was impossible to acquire detailed information on a
woman’s sexual behaviour.
Our study found that only 1% of Pap smears were abnor-
mal, which is much lower than would be expected given
the high HPV prevalence and from previous reports in Fiji
where one in 10 Pap smears were abnormal [6], and in
Vanuatu where 13.6% were abnormal [9]. The majority of
the cervical abnormalities in our study were classified as
high-grade lesions but the classification could not distin-
guish benign cellular changes from atypical squamous cells
of undetermined significance (ASCUS). This contrasts with
previous studies in Fiji and Vanuatu that found more low-
grade abnormalities [6,9]. These findings highlight, once
again, inherent problems in achieving reproducible stan-
dards of cytological screening in settings where large
quality-assured cervical cancer screening programmes are
not in place [22]. Furthermore, a large number of women
with an abnormal cytology result did not return for follow-
up (11 out of 13). This phenomenon was also reported in
recent studies in Vanuatu [9] and Fiji [6]. The Fijian popu-
lation undertakes a large amount of movement between
family groups and residencies, giving rise to a dynamic and
mobile population. This is a significant cause of the failure
to reach clients to inform them of their results and the
need to return in a timely manner for further manage-
ment/treatment. The sharing of a few common names
among clients is also a real issue since it is difficult to ac-
curately identify individuals. It is routine and necessary
practice in Fiji laboratory request forms to record a client's
father’s name (in Indian Fijian clients) in order to help
identify individuals. It has been recommended [8] that all
clients to be assigned a unique identifier, to assist in identi-
fying patients and tracking test results to assist with
follow-up. Due to high workloads, nurses often view
searching for patients to inform them of their smear results
and to arrange follow-up as a poor use of their time [6].
Conclusion
Cervical cancer is the most common cancer for women
in Fiji. Our findings provide essential information for fu-
ture policy decisions on the most appropriate methods
of cervical cancer prevention in Fiji and in the Pacific re-
gion as a whole, particularly in light of the recent devel-
opment of vaccines against HPV16/18 (which account
for 77% of cervical cancer in Fiji [8]) as well as cheap
and simple HPV-based screening tests designed for low-
and middle-income settings [23]. A relatively high preva-
lence of HR HPV (10%) in women older than 45 sug-
gests a strong incentive not to exclude older women
from at least the first screening round in high-risk and
previously unscreened populations. The choice of HPV-
based primary screening is especially valuable in these
older women in some low-resource countries on account
of the loss of sensitivity of visual inspection techniques
as the squamous–columnar junction withdraws into the
endocervix [24,25]. Difficulties in following-up screen-
positive women in such a high-risk population, also
point to the strong need for access to a rapid HPV test-
ing method that allows see-and-treat approaches at the
same visit. An on-going active education campaign on
the health burden due to cervical cancer (a condition
that is very much preventable through early detection of
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pre-cancerous lesions) and the rationale for regular cer-
vical screening and follow-up for the general population
and health workers would also be highly beneficial.
Materials and methods
At the beginning of every interview and prior to speci-
men collection, individuals were again given one explan-
ation of the objectives and aims of the study where they
gave consent. The study was approved by the National
Health Research Committee of the Ministry of Health of
Fiji and was carried out between July 2010 and February
2011.
Participants
No reliable resident list was available for the study area.
We concentrated, therefore, on invitations through
Table 2 Odds ratios (ORs) for human papillomavirus (HPV) positivity and corresponding 95% confidence intervals (CIs)
according to selected risk factors
Risk factors No.
women
HPV-positive
women
(%) Age-adjusted
OR
95% CI Multivariate
OR*
95% CI
Age-group
16–24 151 54 35.8 1 – 1 –
25–34 435 112 25.8 0.62 0.42–0.93 0.57 0.36–0.89
35–44 311 70 22.5 0.52 0.34–0.80 0.50 0.31–0.81
45–54 277 49 17.7 0.39 0.25–0.61 0.37 0.22–0.61
55–64 70 13 18.6 0.41 0.21–0.82 0.43 0.20–0.89
Chi2(1) for trend = 23.3, p < 0.001
Smoking status
Non–smoker 980 227 23.2 1 –
Ex–smoker 138 37 26.8 1.09 0.72–1.64
Current 125 34 27.2 1.15 0.75–1.77
Marital status
Married 1,027 234 22.8 1 – 1 –
Separated/divorced/widowed 101 28 27.7 1.68 1.04–2.73 1.29 0.71–2.32
Single 116 36 31.0 1.30 0.84–1.99 1.10 0.47–2.57
Age at 1st sexual intercourse (yrs)
<17 107 29 27.1 1 –
17–19 518 119 23.0 0.80 0.49–1.29
>19 602 144 23.9 0.84 0.52–1.35
Chi2(1) for trend = 0.18, p = 0.42
Number of full–term pregnancies
Nulliparous 13 6 46.2 2.17 0.70–6.71
1 263 73 27.8 1 –
2 318 72 22.6 0.84 0.57–1.24
3 220 49 22.3 0.88 0.56–1.37
≥4 323 59 18.3 0.72 0.46–1.13
#Chi2(1) for trend (excluding nulliparous) = 3.80, p = 0.05
Use of hormonal contraceptive
Never 681 173 25.4 1 –
Past 352 79 22.4 0.86 0.63–1.17
Current 210 46 21.9 0.64 0.44–0.95
Husband’s extramarital sexual relationships
No 849 178 21.0 1 – 1 –
Yes 214 63 29.4 1.69 1.20–2.38 1.66 1.17–2.34
*Adjusted for age and the other variables in the table. Women were excluded from the models (e.g. smoking status) if they were missing the variable, so the
different models included different numbers of women. #Trend estimated excluding nulliparous women.
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community meetings, church leaders, public health out-
reach and pamphlets at village shops. We conducted
Pap smears and obtained specimens for HPV testing in
neighbouring villages as well as in the Valelevu Health
Centre. In addition, workers at a garment factory, situ-
ated in the study area (at least half of the employed
women are local), were included in the study.
A standardised questionnaire, similar to that used in
other IARC-coordinated HPV surveys [9], was adminis-
tered to all study participants by trained interviewers. The
questionnaire included questions on socio-demographic
characteristics, sexual behaviour of the women and of
their partners, reproductive factors, use of contraceptive
methods, and smoking habits.
Sample collection
During community meetings, and individually prior to
sample collection, clients were given an information
sheet about the study, which was also explained in Eng-
lish, Fijian or Hindi by one of the public health nurses.
The nurses also did the Pap smears and took the speci-
mens for HPV testing.
The cervical cell sample collection methodology has
been described elsewhere [13]. Briefly, after the prepar-
ation of a Pap smear, the brush containing cellular mater-
ial was placed in a vial containing PreservCyt media
(Hologic, Bedford, MA, USA). The brush was fully rinsed
and shaken in the media to remove any residual cells and
the brush discarded. Cell samples in the PreservCyt media
were transported to the Fiji Ministry of Health Viral La-
boratory the same day and stored at 4°C until air freighted
to IARC (Lyon, France) within six weeks of collection of
the specimen.
Cytology
The Pap smears were read and classified at the main ter-
tiary hospital (Colonial War Memorial Hospital, Suva)
laboratory of Fiji. During a one month period between
September and October 2010 (due to acute laboratory
staff shortage) 70 smears were sent for reporting at
Medlab Pathology, Auburn, Australia which collaborates
with the Fiji laboratory. Women with visible abnormal-
ities or abnormal cytology were managed according to
local protocols.
HPV testing and genotyping
HPV DNA analysis was performed at the VU University
Medical Centre, Amsterdam, The Netherlands according
to a protocol similar to that for previous IARC HPV
prevalence surveys [9,18]. Beta-globin polymerase chain
reaction (PCR) analysis was performed first to confirm
the presence of human DNA in all specimens [19]. Cer-
vical specimens were subject to HPV DNA genotyping,
as described elsewhere [20]. HPV positivity was assessed
by hybridisation of PCR products in an enzyme im-
munoassay (EIA) using two HPV oligoprobe cocktails
Figure 2 Age-specific prevalence of human papillomavirus (HPV) positivity by marital status.
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that, together, detect the HPV types outlined in Table 1.
In addition, HPV positivity was assessed by Southern blot
analysis of PCR products with a cocktail probe consisting
of specific DNA fragments under low stringency condi-
tions, allowing the detection of HPV types not included in
the EIA probe cocktails. Subsequently, GP5+/6+ mediated
PCR was repeated on positive samples in triplicate to gen-
erate sufficient products for typing. After pooling of these
PCR products, typing was performed using EIA and HPV
type-specific oligoprobes for the high-risk (HR) and low-
risk (LR) types described above. HPV types considered HR
for this analysis were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, and 68 [9]. All other types were considered LR.
Statistical analysis
Age-standardised HPV prevalence was estimated to
allow comparisons with other IARC surveys [12], using
five-year age-groups and the World standard population
[26]. Odds ratios (ORs) for HPV positivity (and 95%
confidence intervals (95% CIs)) were estimated using lo-
gistic regression. ORs were adjusted for age in the initial
analyses, and then also for exposure variables which
showed elevated risks in preliminary analyses.
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